Julphar announces 90% increase in revenues for Q2 2020

UAE-based Gulf Pharmaceutical Industries (Julphar), has reported Dhs169.7m in revenues for Q2 2020, marking a 90 per cent increase from Dhs89.2m in Q2 2019, on account of the lifting of the temporary suspension on export of products to Kuwait, Saudi Arabia, Oman and Bahrain earlier this year and growth in several of its core markets.

In addition, Julphar has announced a net loss of Dhs25.6m for Q2 2020, which is an improvement of 73 per cent versus the net loss of Dhs96.2m reported in Q2 2019, achieved due to the increase in net sales, expense reduction and gross margin improvement.

In July, Julphar successfully restructured its capital base following the completion of the rights issue which was oversubscribed by 2.3 times indicating strong investor confidence.

Sheikh Saqer Humaid Al Qasimi, chairman of the board, Julphar, said: “It is deeply encouraging to witness the improvement in sales and reduction of losses over the last quarter, which is testament to the resilience of the company’s business model and exemplary vision. The progress we have achieved is instrumental to sustain our 40-year legacy of providing advanced healthcare solutions globally.”

Dr. Essam Farouk, chief executive officer of Julphar, said: “Following the successful capital restructuring and the return to Saudi Arabia and all GCC markets, we are progressing on plan towards achieving profitability and to further enhance our business performance. By maintaining the course in our transformation, we continue our mission to offer full disease management to the millions of people that we proudly serve locally, regionally, and globally.”

In 2020, Julphar announced the relaunch of over 80 products in Saudi Arabia, Kuwait, Bahrain, and Oman after the confirmation of its full compliance with Good Manufacturing Practices (GMP) through an inspection conducted by the Gulf Health Council (GHC) and the Saudi Food and Drug Authority (SFDA).

The future plans of Julphar focus on the strategic areas of the business as the company divests from non-core subsidiaries, regains market position in Saudi Arabia, Kuwait and Oman, builds new alliances to strengthen the company’s product portfolio, launch new products in core therapeutic areas and invest in capital expenditure.

Julphar’s business is centered on three core units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including gastroenterology, pain management, wound care, antibiotics and cardio-metabolism.